key: cord-0306945-hmbhe361
authors: Gachoud, D.; Pillonel, T.; Gerasimos, T.; Battola, D.; Dumas, D.; Opota, O.; Fontana, S.; Vollenweider, P.; Manuel, O.; Greub, G.; Bertelli, C.; Rufer, N.
title: Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents
date: 2022-04-26
journal: nan
DOI: 10.1101/2022.04.24.22274200
sha: 9a3a87a94e6f2d1c3b06fb980b997514aa9f9866
doc_id: 306945
cord_uid: hmbhe361

Background: Administration of plasma therapy may contribute to viral control and survival of COVID-19 patients receiving B-cell depleting agents that hinder the endogenous humoral response. However, little is known on the impact of anti-CD20 pre-exposition and the use of different sources of plasma (convalescent versus vaccinated) on the kinetics of SARS-CoV-2-specific antibodies and viral evolution after plasma therapy. Methods: Eligible COVID-19 patients (n = 36), half of them after anti-CD20 targeted therapy, were treated with therapeutic plasma from convalescent (n = 17) or mRNA-vaccinated (n = 19) donors. Each plasma-transfused patient was thoroughly monitored over time by anti-S IgG quantification and whole-genome SARS-CoV-2 sequencing. Results: The majority of anti-CD20 pre-exposed patients (15/18) showed progressive declines of anti-S protein IgG titers following plasma therapy, indicating that they mostly relied on the passive transfer of anti-SARS-CoV-2 antibodies. Such antibody kinetics correlated with prolonged infection before virus clearance, contrasting with the endogenous humoral response predominantly present in patients who had not received B-cell depleting agents (15/18). No relevant differences were observed between patients treated with plasma from convalescent and/or vaccinated donors. Finally, 4/30 genotyped patients showed increased intra-host viral evolution and 3/30 included 1 to 4 spike mutations, potentially associated to immune escape. Conclusions: Convalescent and/or vaccinated plasma therapy may provide anti-SARS-CoV-2 antibodies and clinical benefit to B-cell depleted COVID-19 patients. Only a limited number of patients acquired viral mutations prior to clinical recovery, yet our study further emphasizes the need for long-term surveillance for intra-host variant evolution, to guide best therapeutic strategies.

increased intra-host viral evolution and 3/30 included 1 to 4 spike mutations, potentially 48 associated to immune escape. 49

Conclusions: Convalescent and/or vaccinated plasma therapy may provide anti-SARS-CoV-2 50 antibodies and clinical benefit to B-cell depleted COVID-19 patients. Only a limited number 51 of patients acquired viral mutations prior to clinical recovery, yet our study further 52 emphasizes the need for long-term surveillance for intra-host variant evolution, to guide best 53 therapeutic strategies. 54 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint V 2 0 0 4 2 2

Coronavirus disease 2019 (COVID-19) disproportionally affects immunocompromised 56 patients, in the context of their underlying disease, high prevalence of comorbidities, and/or 57 related treatment (1) . Hematological malignancies and solid tumors have been consistently 58 associated with increased risk of COVID-19 complications and death (2-5). Repeated 59 administration of anti-CD20 monoclonal antibody (e.g. rituximab), an effective treatment for 60 B-cell cancers or inflammatory autoimmune diseases, which leads to B-cell lymphopenia and 61 hypogammaglobulinemia, is also marked by a more severe COVID-19 course (6-8) and 62 impaired anti-SARS-CoV-2 antibody response, elicited by infection or vaccination (9, 10). 63

Neutralizing antibodies represent an important correlate of recovery following SARS-CoV-2 64 infection (11). Consequently, convalescent plasma therapy (CP), obtained from donors who 65 have recovered from COVID-19 and containing anti-SARS-CoV-2 neutralizing antibodies, 66

has been under massive investigation as reported in large randomized controlled trials (12-67 18). In immunocompetent COVID-19 patients with high-risk factors for severe disease 68 progression, treatment with CP has shown clinical benefit when given early (within 72 hours 69 after the onset of symptoms) and with high titers of neutralizing antibodies (12, 13). Similar 70 observations were made when REGN-COV2, a neutralizing monoclonal antibody (mAb) 71 cocktail was administrated early in the disease course and in seronegative individuals (19) . 72

Most of these trials, however, failed to demonstrate a therapeutic benefit of CP, once COVID-73 19 patients were hospitalized with an already-established severe pneumonia (14-18). 74

The usefulness of plasma therapy is more substantial in immunodeficient patients. There is 75 growing evidence from cohort studies and case-series, that CP therapy in frail 76 immunosuppressed individuals, unable to mount effective anti-SARS-CoV-2 antibody 77 responses, reduces viral load and improves clinical symptoms, even when given late after 78 initial diagnosis (20-25). Accordingly, these findings suggest that the administration of 79 plasma with high neutralizing antibody titers is a safe and effective treatment for 80 immunosuppressed patients (3, 26, 27) . 81

Patients with immunosuppression are also at specific risk for a protracted infection with 82 SARS-CoV-2 (28). In an initial report, Aydillo et al. showed no major changes in the 83 consensus sequences of the original virus strain from serial sample genomes of 11 84 immunosuppressed patients, including patients treated with CP (29). However, accumulation 85 of SARS-CoV-2 mutations have been documented in sporadic case-reports of long-term 86 infected immunocompromised hosts (30-34). While this phenomenon does not seem to be 87 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. Here, we describe the long-term outcomes of 36 patients with acquired immunodeficiencies 104 (32/36; 89%) or high-risk factors (4/36; 11%) after treatment with convalescent plasma (CP, n 105 = 17) or vaccinated plasma (VP, n = 19), between November 2020 and July 2021. Half of the 106 patients (18/36) had received or were still under anti-CD20 therapy (e.g. rituximab, 107 obinutuzumab). The aims of this study were to determine (i) the feasibility of using different 108 sources of plasma (CP versus VP), (ii) the impact of anti-CD20 pre-exposition on anti-SARS-109

CoV-2-specific antibody kinetics and (iii) the rate of viral evolution and immune escape after 110 plasma therapy in immunosuppressed patients. Therefore, each patient was thoroughly 111 monitored over time by anti-S IgG quantification and whole-genome SARS-CoV-2 112 sequencing. 113 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) autoimmune disease (n = 5) and/or a solid organ transplant (n = 5) and/or active solid tumor 129 malignancy (n = 3) and were hospitalized with mild to severe COVID-19 according to the 130 WHO classification. We included 4 additional non-immunocompromised patients with high-131 risk factors for severe COVID-19 and nosocomial infection < 72h post symptoms or diagnosis 132 (12). Patients included in this analysis were alive on day 7 after plasma transfusion. 133

Convalescent plasma was collected from 32 male donors (CP), who had fully recovered for at 135 least 28 days after COVID-19 onset and presented an anti-S protein-specific IgG response, 136 ranging from 29.4-135.6 ratio, with an average ratio of 79 using an in-house developed 137

Luminex assay (42), correlating to neutralizing titers (43, 44). Due to the difficulties to obtain 138 high-titer plasma from convalescent donors, we collected from March . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) performed with Freebayes (parameters: -min-alternate-fraction 0.1 -min-coverage 10 -min-179 alternate-count 9) (48). Positions covered by less than 10 reads were set to N (unknown) if 180 they were not identified as part of a short deletion by Freebayes. Only variants supported by 181 at least 70% of mapped reads were considered to build consensus genomes. The consensus 182 sequence was generated with bcftools (49), was checked using our in-house quality control 183 (50) and assigned to SARS-CoV-2 lineages with pangolin (51). 184

Single nucleotide variants and indels supported by more than 10% of the reads were 186 compared between sequenced SARS-CoV-2 genomes of each patient. The mutation rate was 187 calculated as the total number of variants supported by >10% of reads present in one or 188 multiple sequenced genomes and absent from the other sequenced genome(s). In addition, the 189 rate of mutations reaching fixation was calculated as the total number of variants supported by 190 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint

Seventeen patients (6 female/11 male) with acquired immunodeficiencies due to 203 hematological malignancy (88%) or autoimmune disease (12%) were treated with 204 convalescent plasma (CP) from November 27, 2020 to March 17, 2021 (Supp. Table 1) . 205

Among them, 12 (71%) had received or still were under anti-CD20 therapy. As the Swiss 206 vaccination campaign started in early 2021, it became possible to collect plasma from SARS-207

CoV-2 vaccinated regular blood donors without a previous history of SARS-CoV-2 infection. 208 (Fig. 1A) . Finally, fewer VP 215 recipients had or were receiving an anti-CD20 antibody treatment (6/19; 32%) and were 216 treated with corticosteroids, remdesivir and/or tocilizumab (47% versus 76%) (Supp. Table  217 1). 218

The majority of patients included in this study had a negative SARS-CoV-2 anti-IgG serology 219 (29/36; 81%) and were not vaccinated (32/36; 89%) ( Fig. 1A) . Most patients had B cell 220 lymphopenia and hypogammaglobulinemia (total IgG) at presentation, both of which were 221 more profound in CP than in VP patients ( Fig. 1B) Anti-CD20 pre-exposition is associated with anti-S IgG titer decay following plasma 234 therapy 235 B-cell depleting treatment such as anti-CD20 targeted therapies represents an important risk 236 factor for severe forms of COVID-19 (8), which may be related to the failure to mount an 237 efficient endogenous anti-SARS-CoV-2 antibody response. To address this hypothesis, we 238 assessed the anti-S IgG titers of each patient treated either with CP or VP at serial time-points 239 following plasma transfusion. While the antibody levels varied greatly between donors of 240 convalescent plasma, these titers were more homogeneous and in general higher in 241 individuals donating plasma after the 2 nd mRNA-based vaccine injection than in unvaccinated 242 convalescent subjects (Fig. 1C-F patients showing a decline in anti-S IgG levels, had been exposed to an anti-CD20 therapy 254 (10/10 CP patients and 5/8 VP patients). In contrast, the other patients (18/36) showed a 255 progressive increase in anti-S IgG titers following plasma transfusion ( Fig. 1E and F indicate that anti-CD20 pre-exposition is associated to a progressive decay in anti-S IgG titers 259 following plasma therapy (CP or VP). 260

At the time of plasma transfusion, patients presented a range from mild to severe COVID-19, 263 according to the WHO classification (CP, mean score at 5, [2 to 9], with 1 mechanically 264 ventilated patient; VP, mean score at 5, [2 to 6]). Three additional patients required 265 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Fig. 2A) . Specifically, low WHO scores, 268 between 0 to 1, were attributed for 12/17 (71%) CP patients and 15/19 (79%) VP patients. 269

Moreover, a favorable trend was generally observed for patients who presented an 270 endogenous serological response, compared to those with anti-S IgG antibody declines (Fig.  271   2A) . Two patients died from SARS-CoV-2-related complications (1 CP; 1 VP) and 5 (2 CP; 3 272 VP) from their primary-evolutive malignancy. 273

Alongside, we observed a gradual decline in SARS-CoV-2 RNA levels from nasopharyngeal 274 swabs, with quantitative values ranging below 10E3 copies/ml in 11 (73%) out of 15 CP 275 patients and 13 (72%) of 18 VP patients ( Fig. 2B and C Fig. 2B and C, see arrows) . Finally, three additional patients (CP-9, VP-9, VP-18), who 283 exhibited persistent SARS-CoV-2 shedding, received repeated transfusions (between 2 to 4-284 times), including plasma from COVID-19 recovered donors boosted by an mRNA vaccine 285 ( Fig. 2D) , leading to the full undetectable SARS-CoV-2 RNA in nasopharyngeal swabs (Fig.  286   2E) . Collectively, prolonged SARS-CoV-2 infection was generally observed in the subgroup 287 of patients displaying a progressive decline in anti-S IgG titers following plasma therapy, 288 including the six patients, receiving serial plasma transfusions. With the exception of three 289 patients (VP-7, VP-9 and VP-11), all were pre-treated with anti-CD20. 290

Only a minority of patients, unable to mount an endogenous humoral response, 291 presented significant viral evolution following plasma therapy 292

To investigate whether persistent SARS-CoV-2 infection was associated with intra-host 293 mutation rate following plasma treatment (Fig. 3) Twenty-six out of 30 patients showed one or more intra-host mutations in the viral 297 subpopulations (>10% reads) at any time-point (Fig. 3A) , some of which reached fixation 298 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. including 20 to 50 that reached fixation for at least one sample time (Fig. 3A, Supp. Table 2) . 303

Phylogenetic analyses with the most closely-related published genomes from Switzerland 304 supported the monophyletic origin of each strain documented in patients CP-9, VP-9 and VP-305 18, hence excluding secondary infections with other circulating strains (Supp. Fig. 1 . 3E) . Viral subpopulations tend to disappear at day 3 following VP treatment, but a very 317 high number of mutations supported by 10-70% of the reads were detected again at day 7. 318 VP-18 also presented an intriguing pattern of mutation acquisition and alternation over time 319 (Fig. 3F) . In this patient, two distinct mutation profiles were observed alternatively at 320 different time-points (day 61/67/77/91/102 and 83/109), also supported by phylogenetic 321 analyses (Supp. Fig. 1) . In spite of this viral diversification, consecutive plasma transfusion 322 from different donors, including convalescent vaccine-boosted plasma (CP/V), led to SARS-323

CoV-2 infection control (Fig. 2E) . 324

Only a limited number of spike mutations were globally observed during the follow-up (Fig.  325   3D ) and were composed of amino-acid substitutions and several recurrent deletions within the 326 N-terminal domain of the spike protein (e.g. ΔL141-Y144, ΔY145, ΔA243-L244) (Supp. 327 Table 2 ), in line with previous studies (54). Five mutations (S373L, D405N, D427Y, L452R, 328 S494L) were included in the receptor-binding domain (RBD). Patients CP-9 and VP-9 329 acquired 1 and 2 spike mutations, respectively, at late time-points following plasma treatment 330 (Supp. Fig. 2 and 3) . Patient VP-18 presented up to 18 spike mutations, among which 10 331 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint V 2 0 0 4 2 2 1 2 appeared before plasma treatment (Supp Table 2 , Supp. Fig. 3) . Mutation L452R was 332 acquired on day 83, while ΔL141-Y144, ΔY145 and ΔA243-L244 emerged before plasma 333 treatment (< day 64), yet all four play a potential role as immune escape mutations (54, 55). 334

Patient CP-5 developed 2 novel mutations, among which ΔY145 likely contributes to immune 335 evasion (Supp. Fig. 2 and 3) (56). At that time, no second plasma treatment was given, due 336

to the transition to palliative care for her primary evolutive hematological malignancy. 337

Similarly, ΔL141-Y144 deletion, associated to immune resistance after convalescent plasma 338 (54), appeared in another treated patient (CP-14) (Supp. Fig. 2 and 3) . Overall, our 339 observations indicate that only few immunosuppressed patients presented an accumulation of 340 many mutations over the course of the infection, some of which reached fixation. Patients 341 with progressive anti-S IgG antibody declines following plasma therapy were at highest risk 342

for enhanced viral evolution. 343

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. performed. Our study revealed that the majority (15/18) of patients pre-exposed to anti-CD20 353 therapies were unable to mount an effective intrinsic humoral response. Nevertheless, 86% of 354 these patients showed viral titer reduction presumably due to the passively transferred 355 neutralizing antibodies. Owing to an insufficient clinical and microbiological response, six of 356 them received additional plasma transfusions but still presented after each treatment, 357 progressive declines in their anti-S IgG titer response. Conversely, a long-term rise in anti-S 358 IgG antibody titers was more frequently observed in non CD20-exposed patients (15/18), and 359 was indicative of an ongoing endogenous response (Fig. 1) . Overall, 34 of 36 (94%) patients 360 had an improved WHO clinical score within 30 days after plasma therapy and among them, 361 87% (27/31, excluding 3 patients with undetectable viral loads before plasma transfusion) 362 presented no SARS-CoV-2 RNA detection by PCR (Fig. 2) with high and homogenous anti-S protein IgG titers post-second mRNA vaccination (Fig. 1)  373 (i.e. with high neutralizing titers (40, 41)). In the meantime, two doses of mRNA vaccines 374 were shown to remain highly effective against symptomatic SARS-CoV-2 infection and 375 severe outcomes with different variants of concern (59, 60). Moreover, a single immunization 376 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. can boost the neutralizing titers up to 1000-fold in COVID-19-recovered donors (61). When 377 administrated to immunosuppressed patients, comprising those who received an anti-CD20 378 pre-treatment, vaccinated plasma allowed the efficient transfer of anti-S IgG antibodies and 379 led to clinical and viral load recovery comparable to CP therapy ( Fig. 1 and 2) . In addition, 380 three cases presenting persistent SARS-CoV-2 infection were efficiently treated with 381 convalescent vaccine-boosted plasma (Fig. 2) have not been exposed (61-63) and is currently the only source of plasma. 388

Only a minority of the 30 genotyped patients displayed an increased viral mutation rate (Fig.  389 3), most of whom were unable to mount an intrinsic antibody response to SARS-CoV-2. 390

Likewise, whole-genome sequencing showed the emergence of a limited number of spike 391 mutations (e.g. ΔL141-Y144, ΔY145 and L452R) potentially associated to immune escape, in 392 different patients (CP-14, CP-5 and VP-18, respectively) following plasma therapy (Fig. 3) . . Table 2 ). Consistently, only 5 of the 31 405 identified spike mutations affected the RBD region. In line with these observations, escape 406 from polyclonal plasmas likely involves larger antigenic structural changes than escape from 407 monoclonal Abs, targeting single epitopes (54). As comparable viral evolution patterns were 408 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint V 2 0 0 4 2 2 1 5

found following transfusion with vaccine-based plasma, this also suggests that convalescent 409 and vaccinated plasma may share common mechanisms in antibody-mediated protection. 410

In summary, our case series extends on previous findings (3, 57), validating the concept that 411 immunosuppressed patients, particularly those who are pre-exposed to an anti-CD20 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint

Factors associated 503 with COVID-19-related death using OpenSAFELY

Outcomes of patients with 505 hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 506 patients

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic 509 Cancers and COVID-19

COVID-19 511 infection in adult patients with hematological malignancies: a

Survey (EPICOVIDEHA)

Risk of COVID-19 death in 514 cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London

COVID-19 517 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with 518 rituximab: a cohort study

Persisting SARS-CoV-2 520 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

Prolonged in-hospital 523 stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated 524 with B-cell depleting immunotherapy

Seroconversion 526 rates following COVID-19 vaccination among patients with cancer

Production and 529 persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of 530 rituximab

The antibody response of haematological malignancies to COVID-19 infection 532 and vaccination

Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Convalescent 536 Plasma Antibody Levels and the Risk of Death from Covid-19

Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized 543

Patients With COVID-19 Pneumonia: A Randomized Clinical Trial

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): 576 2021

SARS-CoV-2 Variants 578 in Patients with Immunosuppression

Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Persistence and Evolution 583 of SARS-CoV-2 in an Immunocompromised Host

Case Study: 585 Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised 586 Individual with

SARS-CoV-2 evolution 588 during treatment of chronic infection

Increased viral variants 590 in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 591 infection: A consecutive case series

Long-Term Evolution of 593 SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. mSphere

SARS-CoV-2 596 escape from a highly neutralizing COVID-19 convalescent plasma

Convalescent plasma-599 mediated resolution of COVID-19 in a patient with humoral immunodeficiency

Antibody responses to SARS-602

CoV-2 in patients with COVID-19

Convalescent plasma from people vaccinated after 604 COVID-19 infection

A Little) Clarity on Convalescent Plasma for Covid-19

Safety and 608 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Vaccine against SARS-CoV-2 -Preliminary Report

Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in 614 Population-Based Seroprevalence Studies

A high-throughput cell-616 and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 617 convalescent plasma

Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma 620

Comparison of SARS-CoV-2 RT-PCR on a high-622 throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of 623 COVID-19 on various clinical samples

Viral load of SARS-CoV-2 across patients and 625 compared to other respiratory viruses

Recommendations for 627 accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples

Haplotype-based variant detection from short-read sequencing

Twelve years of 632 SAMtools and BCFtools

Assessment of SARS-CoV-2 Genome Sequencing

Quality Criteria and Low-Frequency Variants

Assignment of 636 epidemiological lineages in an emerging pandemic using the pangolin tool

Nextstrain: real-time 639 tracking of pathogen evolution

641 Temporal signal and the phylodynamic threshold of SARS-CoV-2

Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review

Variants and Their Relevant Mutational Profiles: Update Summer 2021

N-terminal 650 domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Convalescent plasma 653 improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a 654 longitudinal cohort and propensity score analysis

CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics

Time Course of SARS-CoV-2 Neutralizing Antibodies

Effectiveness 660 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of COVID-662 19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of 663 concern in Ontario

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.24.22274200 doi: medRxiv preprint